Lung Transplantation for Pulmonary Langerhans' Cell Histiocytosis: A Multicenter Analysis

2006187 citationsJournal Article

Authors

Gaëlle Dauriat · Assistance Publique – Hôpitaux de Paris

Hervé Mal · Assistance Publique – Hôpitaux de Paris

Gabriel Thabut · Assistance Publique – Hôpitaux de Paris

Jean‐François Mornex · Hospices Civils de Lyon

Michelle Bertocchi · Hospices Civils de Lyon

François Tronc · Hospices Civils de Lyon

François Leroy-Ladurie

Abstract

Severe pulmonary hypertension is a common feature in patients with end-stage PLCH. Given the good postransplant survival rate and despite a recurrence rate of the disease of approximately 20% after LT, we conclude that LT is a therapeutic option in this setting.

Topics & Keywords

Histiocytic Disorders and Treatments Transplantation: Methods and Outcomes Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Transplantation

Volume 81, Issue 5, pp. 746-750

DOI: 10.1097/01.tp.0000200304.64613.af

Field-Weighted Citation Impact: 3.45